Recognition and Importance of New Definitions of Peripancreatic Fluid Collections in Managing Patients with Acute Pancreatitis

Akram Ahmed  Waleed Gibreel  Michael G. Sarr
Department of Surgery, Mayo Clinic, Rochester, Minn., USA

Introduction

The management of pancreatic and peri-pancreatic collections that complicate acute pancreatitis, chronic pancreatitis, pancreatic surgery and pancreatic trauma have been the subject of considerable controversy in the literature. Reasons for this controversy include the following: different techniques of management, different etiologies, different parochial views/beliefs in their natural history, etc. But one of the major reasons for apparent differences in treatment and primarily outcomes are secondary to miscommunication between groups and marked differences in the understanding of much of the terminology used in the past and currently to describe these collections. To date, there has been no universally accepted classification of these collections. All too often, these collections, despite being combinations of both liquid and solid components, are labeled under the non-specific global terms ‘pancreatic pseudocyst’ or ‘pancreatic (or peri-pancreatic) fluid collections’. Unfortunately, these terms, when used indiscriminately in these clinical scenarios, are potentially confusing and misleading to surgeons. The term ‘pancreatic pseudo-
cyst’ to most pancreatologists represents a very specific term, implies a different pathogenesis than the other collections and is managed differently than the other pancreatic and peri-pancreatic collections. Similarly, the terms ‘pancreatic pseudocyst’ or ‘pancreatic fluid collection’ implies a ‘fluid’ collection without any solid component, and when used in patients with severe acute pancreatitis, especially if it is necrotizing pancreatitis, is usually not accurate and overlooks the associated solid components that become very important clinically in subsequent management and prognostication. This uncertainty about the nature of these ‘pseudo’ pseudocysts and ‘fluid collections’ has been present for decades in the literature and has led to tremendous confusion in the appropriate management and the understanding of the natural history of these collections. The aim of this review is an attempt to provide an objective understanding of the natural history of these collections.

Why the emphasis on this terminology and this topic? The history of ‘pancreatic pseudocysts’ goes back many years to the era before CT. The diagnosis was made by clinical examination (a palpable mass) or by an upper gastrointestinal contrast examination showing displacement of the stomach or the duodenum by a non-visualized, extraluminal mass. Introduction of cross-sectional imaging, first transcutaneous ultrasonography (U/S), then CT and now MRI and endoscopic U/S allow the imaging of organs in spaces outside the gut lumen, thereby providing the ability to ‘see’ fluid collections in and around the pancreas. Use of intravenous contrast during the CT also allowed visualization of vascular perfusion of the pancreatic parenchyma by use of intravenous contrast agents, which for once allowed the recognition of actual pancreatic parenchymal necrosis non-invasively early in the course of the disease (the first week) before the need for any operative intervention. This recognition of non-perfusion of the parenchyma also changed our understanding of some elements of the pathogenesis of the disease.

The fact that non-perfusion and hence necrosis of the pancreatic parenchyma can be recognized in as early as the first 12 h using contrast-enhanced CT (CECT) led to the introduction of a new term – ‘necrotizing pancreatitis’, which implied an ischemic phenomenon and not the now outdated misnomer of ‘hemorrhagic pancreatitis’. Unfortunately, many physicians assumed that the ‘necrosis’ only involved the pancreatic parenchyma, and any other fluid or partially fluid-filled collection was a ‘pancreatic pseudocyst’ or (worse yet!) a ‘phlegmon’. This confusion arose, because ‘perfusion’ of the peri-pancreatic retroperitoneal fat is not visible normally, and the peri-pancreatic retroperitoneal fat does not ‘enhance’ with intravenous contrast; thus the lack of perfusion (and thereby the viability) of the peri-pancreatic fat cannot be evaluated directly. Although all surgeons who operated on severe acute pancreatitis or ‘pancreatic abscess’ knew that severe pancreatitis usually had associated ‘fat necrosis’, the ‘necrosis’ of this fat is not an objective diagnosis able to be made on CECT, but can be assumed with insight into the natural history of the disease combined with the clinical presentation. In addition, the appreciation of peri-pancreatic necrosis in the absence of peri-pancreatic parenchymal necrosis was not really accepted until the paper by Sakorafas et al. [3] was published in 1999 and more recently reinforced by others [4]. Since then, our understanding of acute necrotizing pancreatitis has evenuated in the revision of the original 1992 Atlanta Classification [1, 2], which did not recognize/acknowledge this concept of peri-pancreatic necrosis [1, 5] and tried to introduce new terms that further confused the issue [6].

Why the emphasis on this terminology and this topic? The history of ‘pancreatic pseudocysts’ goes back many years to the era before CT. The diagnosis was made by clinical examination (a palpable mass) or by an upper gastrointestinal contrast examination showing displacement of the stomach or the duodenum by a non-visualized, extraluminal mass. Introduction of cross-sectional imaging, first transcutaneous ultrasonography (U/S), then CT and now MRI and endoscopic U/S allow the imaging of organs in spaces outside the gut lumen, thereby providing the ability to ‘see’ fluid collections in and around the pancreas. Use of intravenous contrast during the CT also allowed visualization of vascular perfusion of the pancreatic parenchyma by use of intravenous contrast agents, which for once allowed the recognition of actual pancreatic parenchymal necrosis non-invasively early in the course of the disease (the first week) before the need for any operative intervention. This recognition of non-perfusion of the parenchyma also changed our understanding of some elements of the pathogenesis of the disease.

The fact that non-perfusion and hence necrosis of the pancreatic parenchyma can be recognized in as early as the first 12 h using contrast-enhanced CT (CECT) led to the introduction of a new term – ‘necrotizing pancreatitis’, which implied an ischemic phenomenon and not the now outdated misnomer of ‘hemorrhagic pancreatitis’. Unfortunately, many physicians assumed that the ‘necrosis’ only involved the pancreatic parenchyma, and any other fluid or partially fluid-filled collection was a ‘pancreatic pseudocyst’ or (worse yet!) a ‘phlegmon’. This confusion arose, because ‘perfusion’ of the peri-pancreatic retroperitoneal fat is not visible normally, and the peri-pancreatic retroperitoneal fat does not ‘enhance’ with intravenous contrast; thus the lack of perfusion (and thereby the viability) of the peri-pancreatic fat cannot be evaluated directly. Although all surgeons who operated on severe acute pancreatitis or ‘pancreatic abscess’ knew that severe pancreatitis usually had associated ‘fat necrosis’, the ‘necrosis’ of this fat is not an objective diagnosis able to be made on CECT, but can be assumed with insight into the natural history of the disease combined with the clinical presentation. In addition, the appreciation of peri-pancreatic necrosis in the absence of peri-pancreatic parenchymal necrosis was not really accepted until the paper by Sakorafas et al. [3] was published in 1999 and more recently reinforced by others [4]. Since then, our understanding of acute necrotizing pancreatitis has evenuated in the revision of the original 1992 Atlanta Classification [1, 2], which did not recognize/acknowledge this concept of peri-pancreatic necrosis [1, 5] and tried to introduce new terms that further confused the issue [6].

Our current understanding of this classification of acute pancreatitis is the following (table 1). The process is either an edematous pancreatopathy without necrosis or even much active inflammation (hence the term ‘interstitial edematous pancreatitis’), or it is a ‘necrotizing pancreatitis’ with the necrosis affecting: (1) some of the pancreatic parenchyma and the peri-pancreatic tissues (about 80% of cases), (2) only the peri-pancreatic tissues with no evident pancreatic parenchymal necrosis (about 20%) or (3) rarely, just the pancreatic parenchyma alone (<5%). With this current understanding, most CECTs combined with the clinical scenario can be interpreted according to this new classification of acute pancreatitis based on insight into appearances on CECT [4]. Despite no obvious contrast enhancement or lack thereof in these retroperitoneal tissues, the appearance of what in the past was termed a phlegmon is now recognized as peri-pancreatic necrosis leading to the new term ‘acute necrotic collection (ANC)’, which brings in a different etiology, treatment and prognosis into the clinical scenario, which differs markedly from that of a true pancreatic ‘pseudocyst’. With this in mind, much of the past literature on ‘pancreatic pseudocysts’ in the setting of acute pancreatitis needs to be reinterpreted, and the terms ‘phlegmon’, ‘pancreatic abscess’ and ‘hemorrhagic pancreatitis’ should no longer be used.

The suspicion of the different pancreatic and peri-pancreatic collections originating as local complications of acute pancreatitis can be expected usually based on the clinical presentation, but abdominal imaging has become the cornerstone of diagnosis. CECT remains the diagnos-
tic modality of choice at most centers, although MRI is appropriate in centers with expertise with this technique and may in the future replace CECT. For CECT, the pancreas is best visualized during the portal venous phase, which is about 60–75 s after intravenous contrast injection. The normal pancreas shows complete enhancement with a density between 100 and 150 Hounsfield units. Pancreatic necrosis appears as areas that lack enhancement with the intravenous contrast material. Other diagnostic modalities, U/S and MRI, can serve as adjuncts to CECT and will often visualize the solid and liquid components better than CECT; unfortunately, U/S is all too often obscured by overlying gas, while MRI is less readily available, more expensive and requires expertise in its interpretation both by the radiologist and the surgeon. For these reasons, CECT will be the focus in this review, highlighting the characteristic radiologic features of the different pancreatic and peri-pancreatic collections. Based on the new understanding and classification of acute pancreatitis, combined with the correct interpretation of those radiologic findings, 4 different entities of pancreatic and peri-pancreatic collections with specific descriptive terms can be characterized.

Terminology of Pancreatic and Peri-Pancreatic Collections

Acute Peri-Pancreatic Fluid Collections
Etiopathogenesis

Acute peri-pancreatic fluid collections (APFCs) can complicate acute interstitial edematous pancreatitis and can be evident in up to 30–50% cases of acute interstitial edematous pancreatitis [1]. These collections develop early after the onset of pancreatitis due to extravasation of fluid secondary to an increased capillary permeability associated with the pancreatic injury. Very little direct acinar cell necrosis occurs via the pathogenesis of interstitial acute pancreatitis. This pathogenesis is basically a different process than acute necrotizing pancreatitis. These non-localized fluid collections (APFCs) lack an encapsulated wall and usually lie within the confines of tissue planes. Interestingly, the fluid does not contain an increased activity of pancreatic enzymes. The pancreas usually shows features consistent with interstitial edematous pancreatitis, and the pancreatic parenchyma enhances completely without evidence of necrosis; there may, however, be a bit more patchy enhancement due to the edema in the interstitium. A solid component is absent from an APFC. When solid components are present, the diagnosis of APFC should be questioned.

Imaging Characteristics

APFCs appear as ill-defined fluid collections developing between tissue planes (table 2). These collections lack a ‘wall’ or ‘encapsulation’ and appear to ‘dissect’ along defined transitions from the pancreatic parenchyma and the peri-pancreatic tissues (fig. 1). There is usually also an element of pancreatic parenchymal ‘edema’ as well.

Natural History

The natural history of APFCs usually follows a gradual course of spontaneous resolution. Among patients who develop an APFC, about 70% show complete resolution within 2 weeks from the onset of pancreatitis [7]. If the collection persists beyond 4 weeks, it is likely to become encapsulated and at this stage is called a pancreatic pseudocyst. Of note, the progression to pancreatic pseudocyst is a rare occurrence (about 7%) in patients who initially develop APFCs. There are no known factors that predict progression of an APFC to a pancreatic pseudocyst able to be determined by our classic methods of imaging (CT, MRI, U/S).

Peri-Pancreatic Pseudocysts
Etiopathogenesis

When acute peri-pancreatic fluid collections persist beyond 4 weeks, they have typically developed a recognizable wall of inflammatory, reactive granulation tissue. This ‘pseudocyst’ lacks an epithelial lining, which differentiates it from a true pancreatic cyst. The majority of classic pancreatic pseudocysts complicates acute interstitial edematous pancreatitis and develops as a result of

---

**Table 1. Terminology of acute pancreatitis – revised Atlanta classification [5]**

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute pancreatitis</td>
<td>Acute interstitial pancreatitis</td>
</tr>
<tr>
<td>Acute necrotizing pancreatitis</td>
<td>Acute parenchymal necrosis alone</td>
</tr>
<tr>
<td></td>
<td>Pancreatic parenchymal and peripancreatic necrosis</td>
</tr>
<tr>
<td>Pancreatic/peripancreatic collections</td>
<td>APFCs</td>
</tr>
<tr>
<td></td>
<td>Pancreatic pseudocyst</td>
</tr>
<tr>
<td>ANC</td>
<td>WON</td>
</tr>
</tbody>
</table>

---

*a* Acute necrotizing pancreatitis is either sterile or infected.

*b* Collections can be fluid alone, solid elements alone or combination of fluid and solid elements.

*c* Complicate only acute interstitial pancreatitis.

*d* Complicate acute necrotizing pancreatitis.
some type of disruption of the main pancreatic duct or one of its intrapancreatic branches. Although this process during acute pancreatitis obviously involves a focal element of pancreatic parenchymal and/or ductal injury, there is not enough parenchymal injury to be recognized on cross-sectional imaging. Also, these pancreatic pseudocysts complicating acute pancreatitis are located anatomically outside the confines of the pancreatic parenchyma (i.e., peri-pancreatic).

A pancreatic pseudocyst, as defined here, can rarely complicate necrotizing pancreatitis in 2 specific situations. First, when necrotizing pancreatitis involves necrosis of the pancreatic neck that leaves the distal pancreatic remnant viable but ‘disconnected’ from the proximal necrotic pancreas [8], and after resolution of the proximal necrosis, the pancreatic remnant can continue to secrete pancreatic juices leading to a clear fluid collection into a pancreatic ‘pseudocyst’; this clinical scenario has been

Table 2. Shows the time frame of development relative to the onset of pancreatitis, CECT features and natural history of peri-pancreatic fluid collections. The time of onset is defined as the time of onset of abdominal pain

<table>
<thead>
<tr>
<th>Time since onset, weeks</th>
<th>CECT features</th>
<th>Natural history</th>
</tr>
</thead>
<tbody>
<tr>
<td>APFC &lt;4</td>
<td>Homogeneous ill-defined fluid density Lacks encapsulated wall No evidence of pancreatic necrosis (pancreas is completely enhancing)</td>
<td>70% resolve within 2 weeks Progresses to pseudocyst in 7%</td>
</tr>
<tr>
<td>Pancreatic pseudocyst &gt;4</td>
<td>Homogenous rounded fluid density Encapsulated wall Typically peri-pancreatic Complete enhancement of the pancreas with no evidence of necrosis (with 2 exceptions)</td>
<td>Usually resolves Resolution rate is lower if complicates chronic pancreatitis</td>
</tr>
<tr>
<td>ANC &lt;4</td>
<td>Occurs only in the setting of necrotizing Could be intrapancreatic/peri-pancreatic Fluid collection is heterogenous (fluid and non-fluid densities) It lacks a well-defined wall</td>
<td>Evolves into WON after 4 weeks</td>
</tr>
<tr>
<td>WON &gt;4</td>
<td>Heterogenous fluid collection (liquid and non-liquid densities) Completely encapsulated with a well-defined wall Could be intra- or extrapancreatic</td>
<td>About 50% will become secondarily infected</td>
</tr>
</tbody>
</table>

Fig. 1. APFC and pseudocyst. APFC early in course of disease. See rim of fluid outside the pancreatic parenchyma following the peri-pancreatic planes and enhancement of the pancreatic parenchyma.
Importance of Terminology of Collections in Necrotizing Pancreatitis

termed the disconnected duct syndrome. Second, a similar situation can occur in a cavity in the pancreatic or peri-pancreatic region after an operative necrosectomy where all the necrosis has been removed mechanically (necrosectomy) and a ductal disruption persists secreting pancreatic juice into this post-necrosectomy cavity [9]; this form of pancreatic pseudocyst should probably be referred to as a ‘post-necrosectomy pancreatic pseudocyst’, which in itself implies a different pathogenesis.

Because the inflammatory wall of a pseudocyst is actually encapsulating pancreatic exocrine secretions, analysis of the aspirated cavity fluid reveals a very high amylase activity and lipase activity, but most of the other protease enzymes are less stable, and thus amylase activity seems to be the best marker for a pseudocyst.

Imaging Characteristics

Pancreatic pseudocysts complicating acute pancreatitis appear as a well-encapsulated, homogenous fluid density on CECT located outside the confines of the pancreas and specifically with minimal or no intraluminal necrosis or solid matter (fig. 2). The pancreatic parenchyma has a normal contrast enhancement. If the ‘pseudocyst’ cavity contains debris, solid material or necrosis, the term ‘pseudocyst’ should not be used [9]. U/S or MRI may be necessary to exclude the presence of solid components within the pseudocyst cavity. This concept is quite important in differentiating pancreatic pseudocysts from areas of ANCs and from areas of walled-off necrosis (WON). As will be seen below, these latter 2 entities are complications of acute necrotizing pancreatitis: have a different pathogenesis (substantial pancreatic parenchymal or peri-pancreatic tissue necrosis) and portend a greater morbidity and often different treatments. Another characteristic of pseudocysts are that they are typically round without lobulations; in contrast, the necrotic collections complicating necrotizing pancreatitis are often lobulated, less round and multiple.

Natural History

Peri-pancreatic pseudocysts occur in 3% of patients with acute interstitial edematous pancreatitis and in about 7% of cases when APFCs exist initially [7]. Initial studies in the 1970s by Bradley et al. [10] based on U/S reported a high complication rate and low resolution rate when a conservative, non-operative approach to then management of pancreatic ‘pseudocysts’ was followed even for asymptomatic ‘pseudocysts’. These findings led to the adoption of an aggressive operative management over conservative management, but in retrospect, the ma-

majority of patients in this series that stimulated this suggestion of obligate operative intervention were alcoholics diagnosed by U/S, and most of who developed complications probably had necrotizing pancreatitis. Thus, many of these ‘pseudocysts’ were actually areas of ANC or WON. More recent studies by Vitas and Sarr [11] and Yeo et al. [12], however, revealed that most true pancreatic pseudocysts resolve without serious complications when managed non-operatively. Active intervention (endoscopic, percutaneous or open) is reserved for patients with symptoms or with an obviously enlarging pseudocyst. It should be emphasized that conservative management results in a greater resolution rate with pseudocysts originating in the setting of acute interstitial edematous pancreatitis versus pseudocysts arising in the setting of chronic pancreatitis; these latter pseudocysts are often intraparenchymal and involve a different etiopathogenesis.

Acute Necrotic Collections

Etiopathogenesis

ANCs result from acute necrotizing pancreatitis. The necrotizing process can affect the pancreatic parenchyma only, peri-pancreatic tissues only or most commonly both the pancreatic parenchyma and the peri-pancreatic tissues. The neck and proximal body of the pancreatic parenchyma is the anatomic region of the pancreas affected most commonly, while the left aspect of the peri-pancreatic retroperitoneal fat extending down the left gutter and often out along the base of the small bowel mesentery is the peri-pancreatic tissue involved most commonly.
The normal pancreatic microcirculation is disrupted early during the acute necrotizing pancreatitis, and the affected portions of the pancreas, therefore, do not show contrast enhancement during CECT [13]. Whether the disruption of the microcirculation is a result of the acinar cell death or is itself part of the pathogenesis of the acute pancreatitis is unknown. The retroperitoneal ‘fat’ necrosis is a result of extravasation of pancreatic enzymes combined with the inflammatory mediators – cytokines, leukokines, etc. It should be emphasized that in the presence of pancreatic/peri-pancreatic necrosis, ANCs may initially lack a recognizable liquid component, because the full inflammatory response to the acute necrosis is not well established yet. Serial imaging will later reveal the presence of both solid and liquid components. When a solid component is identified, it is appropriate to use the term ANC rather than APFC to describe these collections, because APFCs by definition lack a solid component.

Imaging Characteristics
ANC occur only in the setting of acute necrotizing pancreatitis. After the first several days of the disease, these collections appear as non-homogeneous areas both within and outside the pancreatic parenchyma of both solid and liquid components representative of areas of necrosis, which stimulated an inflammatory influx of cytokines, inflammatory cells and inflammatory exudate (fig. 3, table 2). As time goes on, the liquid component increases further as the process of liquefaction necrosis evolves. These collections, however, can differ substantially in the relative amount of liquid and solid components. For instance, in the first several days of the disease, peri-pancreatic ANCs may not be immediately evident. For instance, ANCs involving the pancreatic parenchyma are more obvious, because the pancreatic parenchyma fails to enhance, indicative of parenchymal necrosis. In contrast, the peri-pancreatic ANCs are not as obvious on CECT very early in the disease, because the peri-pancreatic tissue does not display obvious enhancement with the intravenous contrast agent even under normal circumstances. ANCs may be suspected (and assumed to be present), because they occur in the setting of severe acute pancreatitis [2] and especially when associated with pancreatic parenchymal necrosis (non-enhancement by IV contrast) or when there is what appears to be a thickened ‘inflammatory’ reaction extending down the left or right paracolic gutter on CT [4]. Therefore, the detection and differentiation of ANCs from APFCs can be difficult within the first few days of acute necrotizing pancreatitis;

Fig. 3. ANC. a Sterile ANC. Note both pancreatic and peri-pancreatic non-homogenous collections in head and body/tail region. b WON. Six weeks later, encapsulation of collections. c Infected APN. Note ill-defined collection containing gas.
Importance of Terminology of Collections in Necrotizing Pancreatitis

Natural History
ANCs remain sterile or become infected. The presence or absence of infection can be confirmed either with imaging studies (presence of gas within the collection is considered diagnostic) or the presence of a positive culture on microbiologic analysis of fine needle aspirations of the ANC, which is typically performed under imaging guidance (U/S or CT). As the ANC mature and develop liquefaction necrosis, the body tends to surround these areas by forming a wall of reactive tissues and the ANC then becomes encapsulated. At that stage, the collection is termed WON. With time, the ANC either resorb or develop into a WON.

Walled-Off Necrosis
Etiopathogenesis
ANCs that acquire a wall of reactive tissue are called WON. This term is self-explanatory and denotes the presence of necrosis with a reactive enhancing wall. This process usually takes 3–4 weeks and only arises in the setting of acute necrotizing pancreatitis. WON can involve areas of pancreatic parenchyma, peri-pancreatic tissues or, most commonly, both. Because peri-pancreatic necrosis can variably extend beyond the pancreas, WON can still be seen at sites distant from the pancreas.

Imaging Characteristics
Some combination of solid and fluid components is always present. What differentiates WON from a pancreatic pseudocyst is the presence of necrosis (solid elements) within the collection. As with a pancreatic pseudocyst, WON complicates pancreatic parenchymal necrosis usually or often has a connection with the pancreatic ductal system, but what differentiates WON from a pseudocyst is the presence of necrosis. Because imaging studies, especially CECT, may not always identify the solid component in these peri-pancreatic collections during the later phase of the disease, WON may be described erroneously as a pseudocyst. The objective presence of pancreatic necrosis (lack of enhancement by IV contrast), severe and protracted clinical course, or the later clinical deterioration despite optimal management usually suggest the presence of WON (possibly infected WON) rather than pseudocyst even when CECT findings are equivocal. In these circumstances, obtaining a U/S or MRI may be helpful in identifying the presence of solid components in the pancreatic/peri-pancreatic fluid collections. Distinctions between WON and a pancreatic pseudocyst are of crucial importance, because the management is completely different. For this reason, transabdominal or endoscopic U/S or MRI may be a useful adjunct during this window of the disease to identify the presence of necrosis.

Typically WON appears as heterogeneous collections of both solid and liquid components that have a defined thickened, encapsulating wall (fig. 4, table 2). Unlike pseudocysts, which tend to be round and usually singular, WON is usually often non-round, can have several lobular components to each collection, can be multiple and are ‘multiloculated’ secondary to the associated solid necrotic material within the collection. These WON can be sterile or infected; the presence of gas within the collection is pathognomonic of infected WON (fig. 4).

Natural History
WON complicates acute necrotizing pancreatitis and not acute interstitial edematous pancreatitis. Because necrotizing pancreatitis is associated with greater morbidity and mortality, the presence of WON is a marker of overall potential disease severity. As with ANC, WON remains sterile or becomes infected.

About 20–30% of WON will become secondarily infected and usually requires some form of active, intervention- nal necrosectomy – operative, endoscopic, laparoscopic or percutaneous. What is most important about WON is that its treatment is very different from that of a pancreatic...

Fig. 4. WON. Note fluid and solid collections with thick walls involving the region of the body of the pancreas.
pseudocyst in concept. Pancreatic pseudocysts that require treatment for pain or size-related symptoms can be managed by endoscopic (or operative) internal drainage alone. In contrast, WON forms a formal necrosectomy with removal/debridement of necrosis within the collections; simple internal drainage with, for instance, a transgastric, endoscopically-placed stent will likely convert a sterile WON into an infected WON. Therefore, transgastric endoscopic treatment of localized WON involves a much greater endoscopic access into the collection, which allows the necrotic tissue to evacuate into the stomach (or rarely the duodenum) and can be aided by 'driving' the endoscope into the collection combined with the use of mechanical means of endoscopic necrosectomy [14].

**Summary/Overview**

The last 2 decades of experience since the original Atlanta Classification in 1992 [1] have taught us as pancreatologists that many of our concepts of acute pancreatitis were naive and even incorrect [2]. We now know that there are 2 basic forms of acute pancreatitis that denote different natural histories and prognoses – acute interstitial edematous pancreatitis and acute necrotizing pancreatitis. The pancreatic and peri-pancreatic collections that complicate acute pancreatitis are usually not pancreatic pseudocysts – and this term should be reserved for the very special peri-pancreatic fluid collection with minimal or no necrosis that is a rare later (>4 weeks) complication of acute interstitial edematous pancreatitis, which usually does not require active intervention. In contrast, the collections, both peri-pancreatic and pancreatic, that complicate acute necrotizing pancreatitis, ANC and WON, are not pseudocysts and may very well (20–30%) require active intervention by some form of active necrosectomy. Recent work has shown that some respond to antibiotic treatment alone, while most require either percutaneous, endoscopic, minimal access 'step up' treatment [15] or formal operative necrosectomy [16–18]. The old non-specific term of 'phlegmon' is no longer appropriate, and we now understand that patients in the past who had a 'phlegmon' probably had a peri-pancreatic ANC. The treatment of pancreatic and peri-pancreatic collections are different depending on the setting (acute interstitial edematous pancreatitis vs. acute necrotizing pancreatitis). These terms APFC, pancreatic pseudocyst, ANC and WON should be used carefully and specifically.

**Disclosure Statement**

None.

**References**


